These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3607300)

  • 21. Designing and analyzing clinical trials which allow institutions to randomize patients to a subset of the treatments under study.
    Schoenfeld DA; Gelber RD
    Biometrics; 1979 Dec; 35(4):825-9. PubMed ID: 526527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial.
    Weir CJ; Lees KR
    Stat Med; 2003 Mar; 22(5):705-26. PubMed ID: 12587101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bias in treatment assignment in controlled clinical trials.
    Chalmers TC; Celano P; Sacks HS; Smith H
    N Engl J Med; 1983 Dec; 309(22):1358-61. PubMed ID: 6633598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New algorithm for treatment allocation reduced selection bias and loss of power in small trials.
    Hofmeijer J; Anema PC; van der Tweel I
    J Clin Epidemiol; 2008 Feb; 61(2):119-24. PubMed ID: 18177784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive regression.
    Proschan MA; Leifer E; Liu Q
    J Biopharm Stat; 2005; 15(4):593-603. PubMed ID: 16022165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomization procedures in orthopaedic trials.
    Randelli P; Arrigoni P; Lubowitz JH; Cabitza P; Denti M
    Arthroscopy; 2008 Jul; 24(7):834-8. PubMed ID: 18589273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Various randomized designs can be used to evaluate medical tests.
    Lijmer JG; Bossuyt PM
    J Clin Epidemiol; 2009 Apr; 62(4):364-73. PubMed ID: 18945590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials.
    Gail MH
    Cancer Treat Rep; 1985 Oct; 69(10):1107-13. PubMed ID: 4042091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review on the design and reporting of studies on drug-gene interaction.
    Smits KM; Schouten JS; Smits LJ; Stelma FF; Nelemans P; Prins MH
    J Clin Epidemiol; 2005 Jul; 58(7):651-4. PubMed ID: 15939214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The methodologic quality of randomization as assessed from reports of trials in specialist and general medical journals.
    Schulz KF; Chalmers I; Altman DG; Grimes DA; Doré CJ
    Online J Curr Clin Trials; 1995 Aug; Doc No 197():[81 paragraphs]. PubMed ID: 8542098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
    Chau I; Norman AR; Cunningham D; Waters JS; Oates J; Ross PJ
    J Clin Oncol; 2004 Jun; 22(12):2395-403. PubMed ID: 15197201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A treatment allocation procedure for sequential clinical trials.
    Begg CB; Iglewicz B
    Biometrics; 1980 Mar; 36(1):81-90. PubMed ID: 7370375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors in clinical cancer trials.
    Estey E
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2591-3. PubMed ID: 9815662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial designs for predictive marker validation in cancer treatment trials.
    Sargent DJ; Conley BA; Allegra C; Collette L
    J Clin Oncol; 2005 Mar; 23(9):2020-7. PubMed ID: 15774793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and analysis of controlled clinical trials in rheumatic diseases.
    Williams HJ; Reading JC; Ward JR
    Clin Rheum Dis; 1983 Dec; 9(3):499-514. PubMed ID: 6606530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Methodological deficiencies in clinical trials].
    Nahler G
    Fortschr Med; 1992 Oct; 110(28):511-4. PubMed ID: 1398408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal methods for evaluating therapy.
    Clemens JD; Horwitz RI
    Biomed Pharmacother; 1984; 38(9-10):440-3. PubMed ID: 6529601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ethics of randomization].
    Arpaillange P; Dion S
    Biomed Pharmacother; 1984; 38(9-10):426-9. PubMed ID: 6529599
    [No Abstract]   [Full Text] [Related]  

  • 39. Biostatistical aspects of adjuvant therapy assay.
    Hudec M; Platz H
    Drugs Exp Clin Res; 1986; 12(1-3):73-81. PubMed ID: 3732057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternatives to randomized clinical trials.
    Ellison GW; Mickey MR; Myers LW
    Neurology; 1988 Jul; 38(7 Suppl 2):73-5. PubMed ID: 3290718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.